Next Generation Antibody Therapeutics Market Segmented By Oncology, Autoimmune/Inflammatory Therapeutic Area with Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments and antibody-like proteins, Antibody fragments and antibody-like proteins Technology
Industry: Healthcare
Published Date: June-2015
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 106
Report ID: PMRREP3713
Chapter 1. Preface 10
1.1. Report Description 10
1.2. Research Methodology 11
1.3. Assumptions 11
Chapter 2. Market Synopsis 12
Chapter 3. Porter’s Five Forces Analysis 14
3.1. Bargaining Power of Suppliers 14
3.2. Bargaining Power of Buyers 14
3.3. Threat of New Entrants 14
3.4. Threat of Substitutes 14
3.5. Intensity of Rivalry 14
Chapter 4. Industry Overview 15
4.1. Market Definition 15
4.2. Market Drivers 17
4.2.1. Growing R&D activities 17
4.2.2. Increasing prevalence of chronic diseases 18
4.2.3. Technological advancements in antibody therapeutics 18
4.2.4. Increasing healthcare expenditure 19
4.3. Impact Analysis of Market Drivers 20
4.4. Restraints 22
4.4.1. Stringent regulatory requirements and long approval times for new drugs 22
4.4.2. High costs of next-generation antibody therapeutics 23
4.5. Impact Analysis of Market Restraints 24
4.6. Market Trends 24
4.6.1. Increasing usage of antibody-drug conjugates (ADC) technology is gaining popularity in next-generation antibody therapeutics market 24
4.6.2. Rising number of collaborations for development of next-generation antibody therapeutics 25
Chapter 5. Major Next-generation Antibody Therapeutics Pipeline Drugs 28
Chapter 6. Global Market Size and Forecast 33
6.1. On the Basis of Geography 33
6.2. On the Basis of Therapeutic Area 34
6.3. On the Basis of Technology 36
Chapter 7. Market Size and Forecast by Therapeutic Area 38
7.1. Oncology 38
7.2. Autoimmune/Inflammatory 40
Chapter 8. Market Size and Forecast by Technology 42
8.1. Antibody-drug conjugates (ADCs) 42
8.2. Bispecific antibodies 44
8.3. Fc engineered antibodies 46
8.4. Antibody fragments and antibody-like proteins 48
8.5. Biosimilar antibody products 51
Chapter 9. Market Size and Forecast by Geography 53
9.1. North America 53
9.2. Europe 56
9.3. Asia 61
9.4. Rest of the World 64
Chapter 10. Competitive Scenario 65
10.1. Competitive Benchmarking 65
10.2. Company Share Analysis 67
Chapter 11. Company Profiles 69
11.1. F. Hoffmann-La Roche Ltd 69
11.1.1. Company Overview 69
11.1.2. Products and services 70
11.1.3. Financial performance 71
11.1.4. Key Developments 71
11.2. Kyowa Hakko Kirin Co., Ltd. 73
11.2.1. Company Overview 73
11.2.2. Products and Services 74
11.2.3. Financial performance 75
11.2.4. Key Developments 75
11.3. Seattle Genetics, Inc. 77
11.3.1. Company Overview 77
11.3.2. Products and Services 77
11.3.3. Financial performance 78
11.3.4. Key Developments 78
11.4. ImmunoGen, Inc. 80
11.4.1. Company Overview 80
11.4.2. Products and Services 80
11.4.3. Financial performance 81
11.4.4. Key Developments 81
11.5. Bristol-Myers Squibb Company 83
11.5.1. Company Overview 83
11.5.2. Products and Services 83
11.5.3. Financial performance 84
11.5.4. Key Developments 84
11.6. Pfizer, Inc. 87
11.6.1. Company Overview 87
11.6.2. Products and Services 87
11.6.3. Financial performance 88
11.6.4. Key Developments 88
11.7. Amgen, Inc. 90
11.7.1. Company Overview 90
11.7.2. Products and Services 90
11.7.3. Financial performance 91
11.7.4. Key Developments 91
11.8. Biogen 93
11.8.1. Company Overview 93
11.8.2. Products and Services 93
11.8.3. Financial performance 94
11.8.4. Key Developments 94
11.9. Bayer AG 95
11.9.1. Company Overview 95
11.9.2. Products and Services 95
11.9.3. Financial performance 96
11.9.4. Key Developments 96
11.10. Xencor, Inc. 97
11.10.1. Company Overview 97
11.10.2. Products and Services 97
11.10.3. Financial performance 98
11.10.4. Key Developments 98
11.11. Takeda Pharmaceuticals Company Limited 99
11.11.1. Company Overview 99
11.11.2. Products and services 99
11.11.3. Financial performance 100
11.11.4. Key Developments 101
11.12. AstraZeneca 102
11.12.1. Company Overview 102
11.12.2. Products and Services 102
11.12.3. Financial performance 103
11.12.4. Key Developments 103
11.13. Dyax Corp. 105
11.13.1. Company Overview 105
11.13.2. Products and Services 105
11.13.3. Financial performance 106
11.13.4. Key Developments 106
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
TABLE 1: Market snapshot: Next-generation antibody therapeutics market, 2015 and 2022 12
TABLE 2: Drivers for next-generation antibody therapeutics market: Impact analysis 20
TABLE 3: Estimated average timelines for clinical trial approval in various countries 22
TABLE 4: Restraints for next-generation antibody therapeutics market: Impact analysis 24
TABLE 5: Major collaborations in next-generation antibody therapeutics market (2012- April 2015) 26
TABLE 6: Global next-generation antibody therapeutics market size, by region, 2010 - 2013 (US$ Mn) 33
TABLE 7: Global next-generation antibody therapeutics market size, by region, 2014 - 2020 (US$ Mn) 34
TABLE 8: Global next-generation antibody therapeutics market size, by therapeutic area, 2010 - 2013 (US$ Mn) 35
TABLE 9: Global next-generation antibody therapeutics market size, by application, 2014 - 2020 (US$ Mn) 35
TABLE 10: Global next-generation antibody therapeutics market size, by technology, 2010 - 2013 (US$ Mn) 37
TABLE 11: Global next-generation antibody therapeutics market size, by technology, 2014 - 2020 (US$ Mn) 37
TABLE 12: Global oncology next-generation Ab therapeutics market size, by region, 2010 - 2013 (US$ Mn) 39
TABLE 13: Global oncology next-generation Ab therapeutics market size, by region, 2014 - 2020 (US$ Mn) 39
TABLE 14: Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2010 - 2013 (US$ Mn) 40
TABLE 15: Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2014 - 2020 (US$ Mn) 41
TABLE 16: Global ADCs market size, by region, 2010 - 2013 (US$ Mn) 43
TABLE 17: Global ADCs market size, by region, 2014 - 2020 (US$ Mn) 43
TABLE 18: Global BsAbs market size, by region, 2010 - 2013 (US$ Mn) 44
TABLE 19: Global BsAbs market size, by region, 2014 - 2020 (US$ Mn) 45
TABLE 20: Global Fc engineered antibodies market size, by region, 2010 - 2013 (US$ Mn) 47
TABLE 21: Global Fc engineered antibodies market size, by region, 2014 - 2020 (US$ Mn) 47
TABLE 22: Global antibody fragments and antibody-like proteins market size, by region, 2010 - 2013 (US$ Mn) 49
TABLE 23: Global antibody fragments and antibody-like proteins market size, by region, 2014 - 2020 (US$ Mn) 49
TABLE 24: Global biosimilar antibody products market size, by region, 2010 - 2013 (US$ Mn) 52
TABLE 25: Global biosimilar antibody products market size, by region, 2014 - 2020 (US$ Mn) 52
TABLE 26: North America next-generation antibody therapeutics market size, by country, 2010 - 2013 (US$ Mn) 54
TABLE 27: North America next-generation antibody therapeutics market size, by country, 2014 - 2020 (US$ Mn) 54
TABLE 28: Europe next-generation antibody therapeutics market size, by country, 2010 - 2013 (US$ Mn) 59
TABLE 29: Europe next-generation antibody therapeutics market size, by country, 2014 - 2020 (US$ Mn) 60
TABLE 30: Asia next-generation antibody therapeutics market size, by country, 2010 - 2013 (US$ Mn) 62
TABLE 31: Asia next-generation antibody therapeutics market size, by country, 2014 - 2020 (US$ Mn) 63
TABLE 32: Major product categories of Roche 70
TABLE 33: Major product segments of Kyowa Hakko Kirin Co., Ltd. 74
TABLE 34: Major product categories of Seattle Genetics, Inc. 77
TABLE 35: Product category of ImmunoGen, Inc. 80
TABLE 36: Major product segments of Bristol-Myers Squibb Company 83
TABLE 37: Major product segments of Pfizer, Inc. 87
TABLE 38: Major product categories of Amgen 90
TABLE 39: Major categories of therapies of Biogen 93
TABLE 40: Major product categories of Bayer AG 95
TABLE 41: Product category of Xencor 97
TABLE 42: Major product categories of Takeda 100
TABLE 43: Major product categories of AstraZeneca 102
TABLE 44: Product category of Dyax Corp. 105
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
FIG. 1: Next-generation antibody therapeutics market: Porter’s five force analysis 14
FIG. 2: Health expenditure as total percentage of GDP, 2002 and 2012 20
FIG. 3: Global next-generation antibody therapeutics market share, by region, by value, 2013 33
FIG. 4: Global next-generation antibody therapeutics market share, by therapeutic area, by value, 2013 34
FIG. 5: Global next-generation antibody therapeutics market share, by technology, by value, 2013 36
FIG. 6: Global oncology next-generation Ab therapeutics market share, by region, by value, 2013 38
FIG. 7: Global autoimmune/inflammatory next-generation Ab therapeutics market share, by region, by value, 2013 40
FIG. 8: Global ADCs market share, by region, by value, 2013 42
FIG. 9: Global BsAbs market share, by region, by value, 2013 44
FIG. 10: Global Fc engineered antibodies market share, by region, by value, 2013 46
FIG. 11: Global antibody fragments and antibody-like proteins market share, by region, by value, 2013 48
FIG. 12: Global biosimilar antibody products market share, by region, by value, 2013 51
FIG. 13: North America next-generation antibody therapeutics market share, by country, by value, 2013 54
FIG. 16: Europe next-generation antibody therapeutics market share, by country, by value, 2013 59
FIG. 17: Asia next-generation antibody therapeutics market share, by country, by value, 2013 62
FIG. 18: Competitive benchmarking of next-generation antibody therapeutics 65
FIG. 19: Global next-generation antibody therapeutics market, by company 2014 (% share) 67
FIG. 20: Sales and net income of Roche, 2012 - 2014 (US$ Mn) 71
FIG. 21: Net sales and net income of Kyowa Hakko Kirin Co., Ltd., 2012 - 2014 (US$ Mn) 75
FIG. 22: Total revenue and net loss of Seattle Genetics, Inc., 2012 - 2014 (US$ Mn) 78
FIG. 23: Total revenue and net loss of ImmunoGen, Inc., 2012 - 2014 (US$ Mn) 81
FIG. 24: Total revenue and net earnings of Bristol-Myers Squibb Company, 2012 - 2014 (US$ Mn) 84
FIG. 25: Revenue and net income of Pfizer, Inc., 2012 - 2014 (US$ Mn) 88
FIG. 26: Revenue and net income of Amgen, 2012 - 2014 (US$ Mn) 91
FIG. 27: Total revenue and net income of Biogen, 2012 - 2014 (US$ Mn) 94
FIG. 28: Net sales and net income of Bayer AG, 2012 - 2014 (US$ Mn) 96
FIG. 29: Revenues and net loss of Xencor, 2012 - 2014 (US$ Mn) 98
FIG. 30: Revenue and net profit of Takeda, 2012 - 2014 (US$ Mn) 100
FIG. 31: Revenue and profit of AstraZeneca, 2012 - 2014 (US$ Mn) 103
FIG. 32: Total revenue and net loss of Dyax Corp., 2012 - 2014 (US$ Mn) 106
